Squamous lung carcinoma data add further weight to promise of Oncolytics' Reolysin
This article was originally published in Scrip
The day after Oncolytics Biotech said it would split the first Phase III clinical trial for Reolysin - the Canadian company's proprietary formulation of human reovirus - into two separate patient groups, it announced positive interim results from a Phase II trial in squamous cell carcinoma of the lung (SCCLC) that justified continuation of the 55-patient study.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.